Author of the publication

Strong control over multiple endpoints: are we adding value to the assessment of medicines?

, and . Pharmaceutical statistics, 12 (4): 189-91 (May 2013)7342<m:linebreak></m:linebreak>JID: 101201192; 2013/01/12 received; 2013/02/13 revised; 2013/04/11 accepted; aheadofprint;<m:linebreak></m:linebreak>Comparacions múltiples.
DOI: 10.1002/pst.1574

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group., , , , , and . Journal of biopharmaceutical statistics, 16 (3): 275-83; discussion 285-91, 293-8, 311-2 (May 2006)5002<br/>LR: 20071115; JID: 9200436; CIN: J Biopharm Stat. 2006 May;16(3):299-309; discussion 311-2. PMID: 16724486; ppublish;<br/>Tipus d'estudis; Dissenys adaptatius.Strong control over multiple endpoints: are we adding value to the assessment of medicines?, and . Pharmaceutical statistics, 12 (4): 189-91 (May 2013)7342<m:linebreak></m:linebreak>JID: 101201192; 2013/01/12 received; 2013/02/13 revised; 2013/04/11 accepted; aheadofprint;<m:linebreak></m:linebreak>Comparacions múltiples.The role of the minimum clinically important difference and its impact on designing a trial., , , and . Pharmaceutical statistics, 10 (3): 250-6 (2011)6155<m:linebreak></m:linebreak>MDCI; Sample size; Tamaño del efecto.Biopharmaceutical Research, Statistics in.. International Encyclopedia of Statistical Science, Springer, (2011)